Phase 3 Chronic Kidney Disease Trial, Recruiting NCT07374042 Sponsor: University Hospital, Clermont-Ferrand Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 3 Chronic Kidney Disease Trial, Recruiting

NCT07374042
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults (men or women) who are over 18 years of age
  • People who have been diagnosed with stage 4 or 5 chronic kidney disease (CKD), meaning their kidneys are working at a low level, as measured by a specific blood test result below 30 mL/min/m²
  • People who are not currently on dialysis or who have not had a kidney transplant
  • People whose daily protein intake is in a specific moderate range (0.6–0.8 grams per kilogram of body weight per day), calculated using a specific medical formula
  • People who have social security coverage
  • People who are willing and able to provide written consent to participate

Who may not be able to join:

  • People who have been hospitalised in the past 3 months
  • People who are currently taking corticosteroids at a dose greater than 7.5 mg per day, or who are taking chemotherapy or immune-suppressing medications
  • People with severe heart failure (classified as NYHA stage 3 or 4) or severe liver failure (classified as Child Pugh B or C)
  • People with breathing difficulties that require ongoing oxygen therapy
  • People who currently have an active infection, an autoimmune disease, or cancer
  • People who are pregnant or breastfeeding
  • Women who could become pregnant and do not meet at least one of the following conditions: being post-menopausal (confirm with trial site for exact definition), having had a permanent sterilisation procedure, or using an effective method of contraception started at least 28 days before joining the trial (confirm with trial site for accepted methods)
  • People with a psychiatric condition or cognitive difficulties that prevent them from being able to give informed written consent
  • People who are not willing to take part in the study
  • People who have a known allergy or sensitivity to the active ingredients in Ketosteril® (a medication used in CKD management)
  • People who have high calcium levels in their blood (hypercalcaemia)
  • People who have low phosphate levels in their blood (hypophosphataemia)
  • People who are under a legal protection order such as guardianship or curatorship

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Julien Aniort, University Hospital, Clermont-Ferrand

Phone: +334.73754.963

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
5 January 2026
Est. completion
1 January 2030

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Appendicular muscle mass measured by DEXA

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov